Sonnet BioTherapeutics, Inc. (NASDAQ:SONN) | WebDisclosure

Basculer en Français

8225	Companies
111034	Keywords
52755	Articles
60940	Press releases

Headlines Articles Press releases Sonnet BioTherapeutics, Inc.

Home
Companies
Sonnet BioTherapeutics, Inc.

BRIEF

published on 05/22/2024 at 13:05, 5 months 16 days ago

Sonnet BioTherapeutics annonce un examen des alternatives stratégiques

Sonnet BioTherapeutics Valeur Pour Les Actionnaires Examen Stratégique Marchés Des Capitaux Chardan Médicaments Immunothérapeutiques
BRIEF

published on 05/22/2024 at 13:05, 5 months 16 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

Strategic Review Sonnet BioTherapeutics Chardan Capital Markets Stockholder Value Immunotherapeutic Drugs
PRESS RELEASE

published on 05/22/2024 at 13:00, 5 months 16 days ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. initiates review of strategic alternatives to maximize stockholder value with financial advisor Chardan Capital Markets. Evaluation may lead to various strategic transactions but no definitive decisions made yet

Strategic Alternatives FHAB Technology Sonnet BioTherapeutics Holdings Inc. Chardan Capital Markets Immunotherapeutic Drugs
BRIEF

published on 05/20/2024 at 15:20, 5 months 18 days ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Clinical Trials Cancer Treatment Immunotherapy Sonnet BioTherapeutics SON-1010
BRIEF

published on 05/20/2024 at 15:20, 5 months 18 days ago

Sonnet BioTherapeutics annonce des données cliniques mises à jour pour SON-1010

Immunothérapie Essais Cliniques Sonnet BioTherapeutics FILS-1010 Traitement Du Cancer
PRESS RELEASE

published on 05/20/2024 at 15:15, 5 months 18 days ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients

Solid Tumors Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug Phase 1 Clinical Trials
BRIEF

published on 05/14/2024 at 22:20, 5 months 24 days ago

Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités

Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF

published on 05/14/2024 at 22:20, 5 months 24 days ago

Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates

Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
PRESS RELEASE

published on 05/14/2024 at 22:15, 5 months 24 days ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN

Financial Results Biopharmaceutical Clinical Trial Sonnet BioTherapeutics Safety Data
BRIEF

published on 05/06/2024 at 13:05, 6 months 1 day ago

Sonnet BioTherapeutics to Present at EF Hutton Annual Global Conference

Biopharmaceuticals Sonnet BioTherapeutics Investor Meetings EF Hutton Conference Innovative Drugs

Accesswire

Published on 11/08/2024 at 12:00, 18 minutes ago

Fusion Energy Agreement Between RSE and BLUE LASER FUSION (USA)
Published on 11/08/2024 at 10:00, 2 hours 18 minutes ago

BluSky Carbon CEO Presents a Case for Climate Tech Optimism
Published on 11/08/2024 at 09:00, 3 hours 18 minutes ago

Greene Tweed Awarded 'Excellence in International Trade' at the 2024 East Midlands Chamber Business Awards
Published on 11/08/2024 at 07:00, 5 hours 18 minutes ago

Polaris Renewable Energy Announces Fixed Income Meetings
Published on 11/08/2024 at 03:00, 9 hours 18 minutes ago

Alset AI Appoints Wall Street Veteran and Venture Executive as President

View all ACCESSWIRE

EQS Group

Published on 11/08/2024 at 12:01, 16 minutes ago

EQS-Adhoc: Borussia Dortmund reports preliminary figures for the first quarter (Q1) of the 2024/2025 financial year
Published on 11/08/2024 at 12:01, 17 minutes ago

Original-Research: Knaus Tabbert AG (von Montega AG): Kaufen
Published on 11/08/2024 at 11:30, 48 minutes ago

Shelly Group: Invitation to unaudited 9M 2024 earnings webcast/call on 14 November 2024
Published on 11/08/2024 at 11:12, 1 hour 6 minutes ago

Original-Research: Masterflex SE (von Montega AG): Kaufen
Published on 11/08/2024 at 11:10, 1 hour 7 minutes ago

Ossiam ESG Shiller Barclays CAPE® Global Sector UCITS ETF: notice of closure

Les Echos

Published on 11/08/2024 at 12:15, 3 minutes ago

Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Published on 11/08/2024 at 12:15, 3 minutes ago

Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Published on 11/08/2024 at 08:00, 4 hours 18 minutes ago

DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
Published on 11/07/2024 at 19:00, 17 hours 18 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/07/2024 at 19:00, 17 hours 18 minutes ago

ALTAREA : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES OCTOBRE 2024

View all LES ECHOS COMFI WIRE